TABLE 3-3 Novel Antipsychotic Medications

Study

Populationa

Arm (N)

Handling of Dropouts and % Completed Tx by Arm

PTSD Outcome Measure

Padala et al., 2006

Female, S&NS abuse

Total (20)

LOCF

CAPS-Total

Risperidone (11)

82%

PL (9)

67%

Bartzokis et al., 2004

Male, combat

Total (65)

Mixed model and ITT

CAPS-Total

Risperidoned (33)

67%

PL (32)

81%

Reich et al., 2004

Female, mixed abuse

Total (21)

Random effects time modeling and LOCF in some cases

CAPS-2

Risperidone (12)

75%

PL (19)

78%

Hamner et al., 2003

Male, combat

Total (40)

LOCF

CAPS-Total

Risperidone (20e)

58%

PL (20f)

66%

Monnelly et al., 2003g

Male, combat

Total (16)

Not clear

PCL-Mh

Risperidone (8)

87.5%

PL (8)

100.0%

Stein et al., 2002i

Male, combat

Total (19)

LOCF

CAPS-Total

Olanzapine (10)

70%

PL (9)

78%

Butterfield et al., 2001

Female, sexual assault, combat (20%)

Total (15)

LOCF

SI-PTSD

Olanzapine (10)

70%

PL (5)

80%

aIn the population column, male alone or female alone denotes that at least 80% of the study population was male or female. If only one trauma type is listed, at least 80% of the study population reported that type of trauma.

bPTSD outcome measure change data were obtained either directly from the study, when provided, or by subtracting data reported at treatment completion (not follow-up data) from baseline data (before treatment began). Average baseline score when reported or when baseline scores for all arms are nearly the same; otherwise, baseline scores listed individually in order of arm.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement